<p>Drug major Sun Pharma on Wednesday said its Japanese subsidiary has launched its specialty product Ilumya, indicated for treatment of plaque psoriasis in adult patients in Japan.</p>.<p>In June this year, Sun Pharma said its subsidiary has got approval from the Japanese government for Ilumya.</p>.<p>In a regulatory filing, Sun Pharmaceutical Industries said its "wholly-owned Japanese subsidiary has launched Ilumya Subcutaneous Injection 100 mg Syringe in Japan for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies".</p>.<p>Junichi Nakamichi, Country Head, Sun Pharma Japan, said: "Ilumya is Sun Pharma's first innovative drug to be launched in the Japanese market".</p>.<p>Psoriasis is a chronic immune disease that appears on the skin.</p>.<p>Shares of Sun Pharma were trading 0.34 per cent higher at Rs 512.20 apiece on BSE.</p>
<p>Drug major Sun Pharma on Wednesday said its Japanese subsidiary has launched its specialty product Ilumya, indicated for treatment of plaque psoriasis in adult patients in Japan.</p>.<p>In June this year, Sun Pharma said its subsidiary has got approval from the Japanese government for Ilumya.</p>.<p>In a regulatory filing, Sun Pharmaceutical Industries said its "wholly-owned Japanese subsidiary has launched Ilumya Subcutaneous Injection 100 mg Syringe in Japan for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies".</p>.<p>Junichi Nakamichi, Country Head, Sun Pharma Japan, said: "Ilumya is Sun Pharma's first innovative drug to be launched in the Japanese market".</p>.<p>Psoriasis is a chronic immune disease that appears on the skin.</p>.<p>Shares of Sun Pharma were trading 0.34 per cent higher at Rs 512.20 apiece on BSE.</p>